B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raises the price target from $204 to $217.
August 10, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Jazz Pharmaceuticals and raises the price target from $204 to $217, indicating a positive outlook for the company.
The raised price target by B of A Securities indicates a positive outlook for Jazz Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100